Summary
MCT8 deficiency, also called Allan-Herndon-Dudley syndrome, is a rare genetic condition that affects how thyroid hormone is transported into the brain as well as other parts of the body. In this condition, the brain does not get enough thyroid hormone for healthy development, while the rest of the body is exposed to high levels of the active form of thyroid hormone (triiodothyronine; T3) that is circulating in the bloodstream. MCT8 deficiency is a genetic condition that most significantly affects boys, although girls can also have a mild form of the condition or even the complete, severe form. MCT8 deficiency is associated with significant abnormalities in brain development with subsequent intellectual disability and reduced muscle movement abilities. In the body, elevated T3 results in increased heart rate, poor weight gain, and irregular heart rhythm and function. Patient’s life span is shortened from an increased risk for, and decreased ability, to fight infections and an increased risk for fatal heart arrythmia.
Description
MCT8 deficiency is a disorder thyroid hormone transport that results in decreased ability of thyroid hormone to enter the central nervous system during the critical period of brain development during the first trimester of pregnancy. The negative impact on brain development is permanent and associated with impaired cognition, to include decreased ability to understand and communicate and decreased muscle tone and strength. In the most severe form, children have trouble holding up their head in an upright position, sitting, walking, and even eating and drinking. Patients are dependent on their care-providers for all aspects of daily living over their lifetime.
In the rest of the body (outside of the brain), defects in MCT8 function lead to increased conversion of the inactive form of thyroid hormone (T4) to T3 resulting in increased heart rate and risk of abnormal heart rhythm (arrhythmia), elevated blood pressure, increased metabolism with poor weight gain (failure to thrive), warm intolerance and muscle wasting with decreased strength and coordination.
MCT8 deficiency was initially named after the three people who recognized the clinical pattern of the disease, Allan-Herndon-Dudley syndrome. MCT8 deficiency is an X-linked condition, which means the gene involved is on the X chromosome. It is caused by changes in a gene called SLC16A2. These changes stop thyroid hormone from moving where it needs to go in the body. The brain does not get enough thyroid hormone, which causes serious problems with brain development. At the same time, the rest of the body gets too much thyroid hormone. This is called thyrotoxicosis. It can cause poor weight gain (failure to thrive), muscle loss, a fast or uneven heartbeat, high blood pressure, and sweating. Because the abnormality in the DNA is on the X-chromosome, mutations of the gene most significantly impact males who only have one X-chromosome. The severity of the signs and symptoms varies based on the specific location of the abnormality in the SLC16A2 gene. With increased genetic testing, we are now recognizing that the range of severity can be broad. In the most severe form, patients will never walk, talk, be capable of eating or drinking without a risk of aspiration, and be fully dependent on their caregivers. In the least-severe form, patients will have mild intellectual disabilities and mild neuromuscular deficits.
In the severe form, which is currently the largest group of known patients, patients with MCT8 deficiency have a reduced life expectancy, with some not surviving childhood. With early diagnosis, good nutrition, respiratory support, and research into new treatment options, many complications can be reduced, and survival may improve.
Signs and Symptoms
Pregnancy and delivery are typically uncomplicated. Thyroid function testing that is performed as part of newborn screening is also normal. Thyroid hormone (T3) levels in the blood usually do not go up until a baby is about 4 months old. But the first signs can show up as early as 2 to 3 months. These may include problems with development, weak muscles (such as poor head control), and poor weight gain (failure to thrive).
Common signs and symptoms include:
- Low muscle tone (the body feels “floppy”) in babies, often followed by very stiff muscles and tight joints later in childhood.
- Missed milestones such as poor head control, not rolling over, sitting, or walking at the expected ages.
- Poor sleep pattern with frequent waking, jerking motions, and inability to self-soothe
- Feeding problems such as weak suck and increased risk for choking, reflux, and aspiration (food or liquid going into the lungs)
- Increased resting heart rate (called tachycardia)
- Poor weight gain, described as failure to thrive.
- Little or no speech, limited eye contact or social response
Other possible symptoms and complications include:
- Uncontrolled movements, twisting postures, or abnormal positioning of the arms and legs (dystonia), as well as spasticity, which means muscles are stiff and hard to move.
- Seizures in some children, especially as they grow older.
- Sweating, and warm skin, which are signs of elevated T3 levels in the body (described as thyrotoxicosis).
- Curved spine (scoliosis), hip dislocation, and fragile bones from long-term movement and muscle problems.
- Intellectual disability, learning disorder
Not every child has all of these features, and some early signs, such as low muscle tone or developmental impairment, can be subtle and look like other brain or muscle conditions.
Causes
MCT8 deficiency is caused by changes (variants or mutations) in a gene called SLC16A2, which provides instructions for making the MCT8 protein. The MCT8 protein is a transporter. It moves thyroid hormones (T4 and T3) into and out of cells. This includes cells in the brain and in many other parts of the body.
There is no known explanation why abnormalities in the SLC16A2 gene develop and because of this there is nothing a parent did or can do to have prevented their child from having this condition; it is a genetic disorder present from conception. The SLC16A2 gene is located on the X chromosome, so this is called an X-linked condition:
- Boys (who have one X chromosome) with a disease-causing variant are affected.
- Girls (who have two X chromosomes) may carry the variant and may have mild or no symptoms. In rare circumstances, some females can be severely affected.
In many families, the variant is inherited from the mother who is a carrier, as a boy receives the X chromosome from the mom and the Y chromosome from the dad. However, in some cases, the change in the SLC16A2 gene happens spontaneously, for the first time in the child. This is called a “de novo” or new variant. A genetic counselor can review family history, arrange testing, and discuss future pregnancy risks and potential options to either avoid having a second child with MCT8 deficiency or determine if there are any clinical trials exploring the treatment of mom’s during pregnancy (www.clinicaltrials.gov).
Laboratory Investigations
Doctors may suspect MCT8 deficiency based on a child’s developmental pattern, movement problems, and a specific pattern of thyroid blood tests. Typical thyroid test results include:
- High levels of T3 (triiodothyronine)
- Low or low-normal T4 (thyroxine)
- Normal or slightly high thyroid-stimulating hormone (TSH)
Thyroid blood tests in MCT8 deficiency show a pattern that is very specific to this condition. Doctors use this pattern to help diagnose it. A genetic test confirms the diagnosis. Genetic testing is now easier to get, so many children are first diagnosed with a genetic test and then have thyroid blood tests. Genetic testing may include:
- Gene panel or whole-exome sequencing that includes the SLC16A2 gene to look for disease-causing variants.
- Testing of the mother to determine carrier status and inheritance.
- Other siblings should also be tested if MCT8 is diagnosed in the family
- Other family members should be informed to allow them to decide on genetic testing when the condition is diagnosed in a family
Imaging and other tests may be used to understand the child’s health and rule out other causes:
- Brain MRI, which may show delayed myelination (delayed development of the brain’s nerve cells “insulation” layer) or other subtle changes.
- Heart tests such as electrocardiogram (ECG) and echocardiogram to assess for rhythm changes (premature atrial contractions), fast heart rate, or heart strain from high T3 levels.
- Swallow studies to assess for the presence or risk of aspiration
- Nutrition assessments to evaluate feeding safety and growth. Early placement of a gastric-tube (G-tube) should be considered to optimize care
Some of these tests are repeated over time to track thyroid levels, heart function, bone health, and growth as the child gets older.
Treatment and Therapies
There is currently no cure that corrects the underlying gene change, but there are ongoing trials of medical treatments that aim to do two things: get more thyroid hormone into the brain, and lower thyroid hormone (T3) in the rest of the body. The goal is to improve health and quality of life. Treatment involves a multi-disciplinary team that includes;
- Neurology with physical, occupational and speech therapy
- Gastroenterology/nutrition
- Cardiology
- Endocrinology
- Genetics
- Orthopedics
- Social work services
- Complex care manager/coordinator
Supportive therapies commonly include:
- Physical, occupational, and speech therapy to help with positioning, muscle tone, feeding, transportation, and communication.
- Medications to manage spasticity, dystonia, seizures, reflux, or constipation as needed.
- Feeding support, such as thickened feeds or placement of a feeding tube (gastrostomy) if a child has severe feeding difficulties or risk of aspiration.
- Equipment such as wheelchairs, standers, braces, and communication devices to support daily activities and participation. Families will need assistance to convert their home and transportation to be handicap accessible
- Hormone treatments try to help thyroid hormone work normally again. The goal is to lower the high T3 in the body and fix the lack of thyroid hormone in the brain.
Traditional thyroid hormone replacement (such as levothyroxine, which is T4) alone is not effective, because the problem is a defect in transporting thyroid hormone into brain cells, not a reduced ability to produce it. A medicine called tiratricol (also called triiodothyroacetic acid) acts like thyroid hormone. It turns on the same “switches” (receptors) in cells that thyroid hormone does. Studies in children and adults show that tiratricol can:- Bring T3 levels back to normal
- Reduce symptoms of thyrotoxicosis (too much thyroid hormone in the body)
- Help people with MCT8 deficiency live longer
In 2025, tiratricol was approved in Europe to treat thyrotoxicosis in people with MCT8 deficiency. In September 2026, the U.S. Food and Drug Administration (FDA) approved it too. It is the first FDA-approved treatment for MCT8 deficiency. Doctors are studying whether starting tiratricol, or other medicines that help thyroid hormone work normally again, early in babies and young children can improve brain development, movement, and growth.
Doctors will discuss available medication options, expected benefits, and possible risks and will monitor thyroid tests, heart function, growth, and development closely over time. Families should talk with their care team about how each medication might affect their child and what side effects to watch for.
Outlook
Children and adults living with MCT8 deficiency have complex medical needs and significant physical and intellectual disabilities. Most will need full assistance with daily care throughout life. Many do not learn to walk or talk, but with supportive therapies, they can make gains in comfort, communication, and interaction with family and caregivers.
Life expectancy can be reduced, mainly because of problems such as poor nutrition, infections, and strain on the heart caused by long-term thyrotoxicosis (too much thyroid hormone in the body outside the brain). Recent studies suggest that treating the thyroid hormone imbalance with medicines that help thyroid hormone work normally again, such as tiratricol, may reduce some complications and help people live longer. Careful long-term follow-up is still needed.
Day-to-day life for families often involves:
- Regular medical visits and therapy
- Handicap assistance equipment needs
- Home nursing support
- Attention to feeding, positioning, skin care, and breathing support (for example, suctioning or home respiratory devices) when needed.
- Close collaboration with early intervention programs, schools, and therapists to create individualized education plans (IEPs) and support participation in school activities.
Families may experience emotional, physical, and financial stress, so connection with social work, counseling, parent-to-parent support, and rare disease or disability organizations can be very helpful.
Current resources include:
Resources
The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.
We are striving to improve the quality of life and potential of our children; support hundreds of families around the world; share hope for a brighter future; learn from our collective experiences and; raise awareness of this ultra-rare condition with doctors, researchers and the general public.
RAISING THE VOLUME on MCT8 deficiency awareness.
Amplify your understanding of the disorder and diagnosis.
Research
ClinicalTrials.gov for MCT8 Deficiency (birth to 17 years)
These are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently.
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.
Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.
For more information about participation in clinical trials, check out our education hub on the topic here.
The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.
References
- Bauer AJ, Auble B, Clark AL, Hu TY, Isaza A, McNerney KP, Metzger DL, Nicol L, Pierce SR, Sidlow R. Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review. Front Pediatr. 2024 Jul 22;12:1444919. doi: 10.3389/fped.2024.1444919. eCollection 2024. PMID: 39132310
- McWalter K, Elloumi HZ, Sidlow R, Willis B, Bauer AJ. The phenotypic spectrum of individuals with SLC16A2 variants in MCT8 deficiency. HGG Adv. 2025 Jul 10;6(3):100455. doi: 10.1016/j.xhgg.2025.100455. Epub 2025 May 13. PMID: 40369875
- Boelaert K, Bauer A, Cappola AR, Chatterjee K, Dietrich JW, Nicol L, Persani L, Razvi S, Stoupa A. Thyrotoxicosis in MCT8 deficiency. J Clin Endocrinol Metab. 2026 Mar 17;111(4):911-921. doi: 10.1210/clinem/dgaf707. PMID: 41508830
- Groeneweg S, van Geest FS, van der Most F, Abela L, Alfieri P, Bauer AJ, Bertini E, Cappa M, Çelik N, de Coo IFM, Dolcetta-Capuzzo A, Dubinski I, Granadillo JL, Hoefsloot LH, Kalscheuer VM, van der Knoop MM, Krude H, McNerney KP, Paone L, Peeters RP, Peters C, Schuelke M, Schweizer U, Sprague JE, van Trotsenburg ASP, Wilpert NM, Zanni G, van Zutven LJCM, Visser WE. MCT8 Deficiency in Females. J Clin Endocrinol Metab. 2025 Dec 18;111(1):e175-e184. doi: 10.1210/clinem/dgaf311. PMID: 40420837
- Freund MET, van der Most F, Groeneweg S, van Geest FS, Visser WE. Thyroid Hormone Analogs: Recent Developments. Thyroid. 2025 Sep;35(9):990-1002. doi: 10.1089/thy.2025.0245. Epub 2025 Jul 14. PMID: 40658132
- van Geest FS, Groeneweg S, Popa VM, Stals MAM, Visser WE. Parent Perspectives on Complex Needs in Patients With MCT8 Deficiency: An International, Prospective, Registry Study. J Clin Endocrinol Metab. 2023 Dec 21;109(1):e330-e335. doi: 10.1210/clinem/dgad412. PMID: 37450560
- Groeneweg S, van Geest FS, Peeters RP, Heuer H, Visser WE. Thyroid hormone transporters. Endocr Rev. 2020;41(2):146-201.
- Remerand G, Saugier-Veber P, Sarret C, et al. Expanding the phenotypic spectrum of MCT8 deficiency: clinical, laboratory, and neuroimaging findings in a cohort of 47 patients. J Clin Endocrinol Metab. 2020;105(8):e3074-e3088.
- NORD. MCT8-Specific Thyroid Hormone Cell Transporter Deficiency. 2025.
- Children’s Hospital of Philadelphia. MCT8 Deficiency/Allan-Herndon-Dudley Syndrome.
This overview is for general information and is not a substitute for advice from your child's care team.
← Back to the Disorder Directory